E Fund Management Co. Ltd. Takes $47,000 Position in Flexion Therapeutics, Inc. (NASDAQ:FLXN)

E Fund Management Co. Ltd. bought a new stake in Flexion Therapeutics, Inc. (NASDAQ:FLXN) in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor bought 5,234 shares of the specialty pharmaceutical company’s stock, valued at approximately $47,000.

Several other institutional investors also recently modified their holdings of the company. Truist Financial Corp boosted its holdings in shares of Flexion Therapeutics by 11.5% in the 4th quarter. Truist Financial Corp now owns 23,972 shares of the specialty pharmaceutical company’s stock valued at $277,000 after buying an additional 2,472 shares in the last quarter. The Manufacturers Life Insurance Company boosted its holdings in shares of Flexion Therapeutics by 10.4% in the 4th quarter. The Manufacturers Life Insurance Company now owns 27,386 shares of the specialty pharmaceutical company’s stock valued at $316,000 after buying an additional 2,591 shares in the last quarter. Snow Capital Management LP boosted its holdings in shares of Flexion Therapeutics by 1.0% in the 4th quarter. Snow Capital Management LP now owns 306,265 shares of the specialty pharmaceutical company’s stock valued at $3,534,000 after buying an additional 3,000 shares in the last quarter. Prelude Capital Management LLC boosted its holdings in shares of Flexion Therapeutics by 13.1% in the 4th quarter. Prelude Capital Management LLC now owns 31,000 shares of the specialty pharmaceutical company’s stock valued at $358,000 after buying an additional 3,600 shares in the last quarter. Finally, Trexquant Investment LP boosted its holdings in shares of Flexion Therapeutics by 14.6% in the 4th quarter. Trexquant Investment LP now owns 29,409 shares of the specialty pharmaceutical company’s stock valued at $339,000 after buying an additional 3,755 shares in the last quarter. Institutional investors and hedge funds own 94.01% of the company’s stock.

FLXN has been the subject of several research reports. Zacks Investment Research downgraded shares of Flexion Therapeutics from a “hold” rating to a “sell” rating in a research report on Thursday, May 6th. Royal Bank of Canada restated a “buy” rating on shares of Flexion Therapeutics in a research report on Sunday, April 18th. Raymond James cut their price objective on shares of Flexion Therapeutics from $18.00 to $16.00 and set a “strong-buy” rating for the company in a research report on Wednesday, April 14th. HC Wainwright restated a “buy” rating on shares of Flexion Therapeutics in a research report on Wednesday, April 14th. Finally, Credit Suisse Group cut their price objective on shares of Flexion Therapeutics from $17.00 to $14.00 and set an “outperform” rating for the company in a research report on Thursday, May 13th. One analyst has rated the stock with a sell rating, one has issued a hold rating, eight have given a buy rating and one has issued a strong buy rating to the company. Flexion Therapeutics currently has a consensus rating of “Buy” and a consensus price target of $19.56.

NASDAQ:FLXN opened at $9.25 on Friday. The firm has a market cap of $461.96 million, a PE ratio of -4.15 and a beta of 1.40. Flexion Therapeutics, Inc. has a fifty-two week low of $6.71 and a fifty-two week high of $14.39. The stock’s fifty day moving average is $8.37.

Flexion Therapeutics (NASDAQ:FLXN) last issued its quarterly earnings data on Wednesday, May 12th. The specialty pharmaceutical company reported ($0.57) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.49) by ($0.08). The company had revenue of $24.59 million for the quarter, compared to analysts’ expectations of $24.61 million. On average, sell-side analysts forecast that Flexion Therapeutics, Inc. will post -1.96 earnings per share for the current fiscal year.

Flexion Therapeutics Company Profile

Flexion Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for the treatment of patients with musculoskeletal conditions in the United States. The company offers ZILRETTA, an intra-articular injection for the management of osteoarthritis (OA) knee pain.

See Also: What Does a Sell-Side Analyst Rating Mean?

Want to see what other hedge funds are holding FLXN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Flexion Therapeutics, Inc. (NASDAQ:FLXN).

Institutional Ownership by Quarter for Flexion Therapeutics (NASDAQ:FLXN)

Receive News & Ratings for Flexion Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Flexion Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.